Drugs / FT538
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05700630 | Jul 2024 | HIV infectious disease, immunodeficiency disease | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded |
| Phase 1 | NCT05708924 | Apr 2023 → Aug 2024 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 1 | NCT04714372 | Nov 2021 → Jan 2024 | acute myeloid leukemia, monocytic leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT05069935 | Oct 2021 → Aug 2023 | cancer | Fate Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT04614636 | Oct 2020 → Jul 2023 | acute myeloid leukemia, plasma cell myeloma | Fate Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2021-07-07 | GT Biopharma, Inc. | Results GT Biopharma Announces Sponsored Research Agreement With Dr. Jeffrey S. Miller Of The University Of Minnesota gtbiopharma.com ↗
TriKE™ improves FT538 iPSC NK cells from Fate Therapeutics in prostate cancer model |
| 2021-05-13 | Fate Therapeutics | Results Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia fatetherapeutics.com ↗
1 of 3 Patients in First Dose Escalation Cohort of FT538 Monotherapy Study Achieved Objective Response with Complete Leukemic Blast Clearance in the Bone Marrow |
| 2021-05-05 | Fate Therapeutics | Regulatory Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗
IND Application Allowed by FDA for FT538 in Solid Tumors |
| 2020-05-20 | Fate Therapeutics | Regulatory Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy fatetherapeutics.com ↗
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT538, the first CRISPR-edited, iPSC-derived cell therapy. |
| 2020-05-11 | Fate Therapeutics | Regulatory Fate Therapeutics Reports First Quarter 2020 Financial Results and Highlights Operational Progress fatetherapeutics.com ↗
IND Application Submitted to FDA for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy , for Multiple Myeloma |
| 2018-12-04 | Fate Therapeutics | Results Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting fatetherapeutics.com ↗
A poster presentation at ASH by scientists from the Company and the University of Minnesota highlighted new in vitro data showing that FT538 in combination with daratumumab is resistant to fratricide and eliminates multiple myeloma cancer cells in a serial re-challenge assay. |
| 2018-11-01 | Fate Therapeutics | Results Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting fatetherapeutics.com ↗
CD38 Deficient, CD16 Engineered NK Cells Exhibit Enhanced Antibody Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab |
All press releases naming this drug 9 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT538 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04614636 ↗ |
| Action | Inhibit | “the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.” NCT05700630 ↗ |
| Modality | Cell therapy | “Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell” NCT04614636 ↗ |
| Route | Intravenous | “FT538 is administered as an IV infusion via gravity” NCT04714372 ↗ |
| Target | CD38 | “the knock-out of CD38 expression prevent anti-CD38 antibody-induced fratricide.” NCT05700630 ↗ |